Neutral
HighTower Advisors LLC raised its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 8.1% in the 4th quarter, Ho...
Bullish
Health Canada has accepted Vertex Pharma's new drug submission for suzetrigine, an acute pain candidate, initiating a regulatory review. This developm...
Vertex Pharmaceuticals (VRTX) stock has experienced recent weakness, dropping approximately 2% over the past month and 8% over the last three months, ...
Bullish
Vertex Pharma is expanding its pipeline beyond its core cystic fibrosis (CF) franchise, focusing on pain, gene editing, and kidney disease. The compan...
Bullish
Vertex Pharma has reported strong quarterly earnings and continued high demand for its cystic fibrosis medications, exceeding market expectations. The...
Bullish
Canada Post Corp Registered Pension Plan significantly increased its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 59.7% in the fourth quarter, bri...
Neutral
An insider at Vertex Pharmaceuticals (NASDAQ: VRTX) has filed a Form 144 indicating proposed sales of common stock tied to restricted stock vesting an...
Mark Bunnage, an insider at Vertex Pharmaceuticals Inc (VRTX), sold a total of 4,239 shares across three separate transactions in February 2026, reali...
Daiwa Securities has revised its price target for Vertex Pharmaceuticals (VRTX) to $555, down from the previous $561, while reaffirming a Buy rating o...
Bullish
Vertex Pharmaceuticals (US92532F1003) saw its shares rise by 1.06% to $453.06 on Nasdaq, driven by robust quarterly earnings of $4.47 per share, surpa...
Bullish
Vertex Pharmaceuticals (VRTX) stock surged 3.77% intraday, driven by robust call options activity and a technical breakout above key resistance levels...
Vertex Pharmaceuticals reported strong Q1 results, exceeding analyst estimates for revenue and adjusted EPS, driven by its cystic fibrosis franchise a...
Vertex Pharmaceuticals (VRTX) is gaining attention after Germany's GKV-Spitzenverband agreed to reimburse CASGEVY, expanding the reach of the gene the...
Bullish
Vertex Pharmaceuticals reported consolidated financial results for the first quarter of 2026, with total revenue increasing 8% to $2.99 billion compar...
Vertex Pharmaceuticals reported Q1 2026 earnings, exceeding EPS forecasts with $4.47 but missing revenue projections at $2.99 billion. The company hig...
Vertex Pharmaceuticals (VRTX) anticipates its 2026 revenue to fall between $12.95 billion and $13.1 billion. This forecast is in line with FactSet's e...
Bullish
Vertex Pharmaceuticals reported strong Q1 2026 financial results, with total revenue increasing 8% to $2.99 billion, driven by continued growth in cys...
Vertex Pharmaceuticals (VRTX) is set to report its Q1 earnings, with analysts expecting a 6.5% year-on-year revenue growth. The company previously bea...
Bullish
Vertex Pharmaceuticals (VRTX) is set to release its Q1 earnings report this Monday, with analysts anticipating a 6.5% year-on-year revenue growth. The...
Bullish
Vertex Pharmaceuticals (VRTX) is gaining attention after the FDA approved expanded use of ALYFTREK for cystic fibrosis patients and Bank of America pr...